2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-106985
    R 116712 195627-15-7 98%
    R 116712 is a highly selective and affinity 5-HT4 receptor ligand. R 116712 can prepare isotopic markers.
    R 116712
  • HY-106995
    PD 172760 200195-01-3 98%
    PD 172760 (CI 1030) is a selective D4 receptor antagonist. PD 172760 along with the action of other neurotransmitter receptors may be important in study psychosis.
    PD 172760
  • HY-107002
    Lergotrile 36945-03-6 98%
    Lergotrile is a potent and orally active dopamine agonist and a prolactin secretion inhibitor. Lergotrile inhibits prolactin release from pituitaries by activating an adenohypophyseal dopamine receptor. Lergotrile has the potential for the research of Parkinson's disease.
    Lergotrile
  • HY-107018
    AR-A 2 220051-79-6 98%
    AR-A 2 is a selective 5-HT1B receptor antagonist, with high affinity to guinea pig cortex 5HT1B/1D and recombinant guinea pig 5-HT1B receptors (Ki=0.24 and 0.47 nM) and with 10-fold lower affinity to guinea pig 5-HT1D receptor (Ki, 5 nM), and shows an EC50 of 4.5 nM for the guinea pig 5-HT1B receptor; AR-A 2 can be used in the research of depression and anxiety.
    AR-A 2
  • HY-107022
    BMS-341400 296250-53-8 98%
    BMS-341400 is an orally active selective phosphodiesterase 5 (PDE5) inhibitor with an IC50 value of 0.3 nM. BMS-341400 reduces the degradation of cyclic guanosine monophosphate (cGMP), thereby enhancing nitric oxide (NO)-mediated relaxation of the smooth muscle of the corpus cavernosum and promoting erection. BMS-341400 can be used to study erectile dysfunction.
    BMS-341400
  • HY-107032
    Amitriptylinoxide 4317-14-0 98%
    Amitriptylinoxide (Equilibrin) is an analogue and metabolite of amitriptyline with similar antidepressant efficacy.
    Amitriptylinoxide
  • HY-107042
    trans-Sobrerol 42370-41-2 99.75%
    trans-Sobrerol (NRM-331) is a potent mucofluidifying agent. trans-Sobrerol demonstrates an anti-amnesic effect by enhancing hippocampal cholinergic signaling, alongside exhibiting anti-tau and anti-Aβ synthesis properties. trans-Sobrerol mitigates memory impairment induced by Scopolamine (HY-N0296). trans-Sobrerol can be used in the research of Alzheimer's disease.
    trans-Sobrerol
  • HY-107043
    7β-Hydroxy-epi-androsterone 25848-69-5 98%
    7β-Hydroxy-epi-androsterone (7β-Hydroxy-EpiA) can bind to ERβ and has anti-inflammatory and neuroprotective properties. 7β-Hydroxy-epi-androsterone is an endogenous androgenic derivative of dehydroepiandrosterone.
    7β-Hydroxy-epi-androsterone
  • HY-107047
    BGC-201259 444667-97-4 98%
    BGC-201259 (RS-1259) is an orally active inhibitor that simultaneously targets acetylcholinesterase (AChE) (IC50 = 101 nM) and serotonin transporter (SERT) (IC50 = 42 nM). BGC-201259 inhibits 5-HT receptor with an IC50 of 90 nM. BGC-201259 exhibits strong weak activity against the NA transporter (IC50 = 7.7 μM), L-type calcium channel (IC50 = 3.6 μM), σ receptor (IC50 = 2 μM), and sodium channel (IC50 = 5.1 μM). BGC-201259 demonstrates synergistic potential in improving cognitive and emotional symptoms by balancing the inhibition of these two targets. BGC-201259 can be used in research on Alzheimer's disease.
    BGC-201259
  • HY-107055
    RTI 336 204069-50-1 98%
    RTI 336 is a phenyltropane analog, as well as a potent and selective dopamine transporter (DAT) inhibitor. RTI 336 inhibits addictive agent induced locomotor activity and self-administration in Lewis rats. RTI 336 exhibits inhibitory effects depending on inherent NAc DAT levels.
    RTI 336
  • HY-107081
    Berupipam hemifumarate 172940-14-6 98%
    Berupipam hemifumarate is a selective antagonist of the dopamine D1 receptor (dopamine D1 receptor). Berupipam hemifumarate is a substrate of UDP-glucuronosyltransferase (UGT) and has a high affinity for UGT enzymes but a relatively low conversion rate. The glucuronidation rate of Berupipam hemifumarate varies among different species and genders. Berupipam hemifumarate can be used for the study of psychotic disorders.
    Berupipam hemifumarate
  • HY-107095
    JNJ19567470 724471-26-5 98%
    JNJ19567470 (R317573) is a selective, non-peptidergic CRF type 1 receptor (CRF1) antagonist. JNJ19567470 blocks NaLac-induced panic-like behaviour and cardiovascular responses. JNJ19567470 decreases regional glucose utilization in the amygdala, and attenuates anxiety responses.
    JNJ19567470
  • HY-107121
    Ondelopran 676501-25-0 98%
    Ondelopran (LY 2196044) is a non-selective opioid receptor antagonist. Ondelopran inhibits the release of dopamine in the nucleus accumbens induced by alcohol, reduces the rewarding effect of alcohol consumption, and lowers the craving. Ondelopran can be used for alcohol use disorder (AUD).
    Ondelopran
  • HY-107125
    AVN-322 1194574-68-9 98%
    AVN-322 is an orally active, highly selective 5-HT6Rantagonist for central nervous system disease research.
    AVN-322
  • HY-107328
    Carumonam disodium 86832-68-0 98%
    Carumonam disodium is a potent antibiotic. Carumonam disodium shows antibacterial activity. Carumonam disodium induces seizure.
    Carumonam disodium
  • HY-107434
    Molindone 7416-34-4 98%
    Molindone ((±)-Molindone), an indole derivative, is a potent dopamine D2 and D5 receptor antagonist. Molindone ((±)-Molindone) can be used for the research of schizophrenia and severe mental illness.
    Molindone
  • HY-107479
    (R)-JNJ-31020028 1094873-17-2 98%
    (R)-JNJ-31020028 is a high affinity, selective brain penetrant neuropeptide Y Y2 receptor antagonist, with pIC50 values of 8.07, 8.22 and 8.21 for human, rat, and mouse Y2 receptor, respectively. (R)-JNJ-31020028 shows >100-fold selective versus human Y1, Y4, and Y5 receptors. (R)-JNJ-31020028 has antidepressant like effects.
    (R)-JNJ-31020028
  • HY-107506
    Ro 67-4853 302841-89-0 99.90%
    Ro 67-4853 is a positive allosteric modulator (PAM) of mGluR1 (pEC50=7.16 for rmGlu1a receptor). Ro67-4853 exhibits activity at all group I mGlu receptors including hmGlu1, rmGlu1, and rmGlu5. Ro 67-4853 enhances the potency of L-Glu by interacting with the transmembrane domain (TMD) of the receptor. Ro 67-4853 potentiates sensory synaptic responses to repetitive vibrissa stimulation.
    Ro 67-4853
  • HY-107513
    BAY 36-7620 232605-26-4 98%
    BAY 36-7620 is a potent and noncompetitive antagonist of mGlu1 Receptor (IC50=0.16 μM) with inverse agonist activity. BAY 36-7620 inhibits tumor growth and prolongs the survival of mice with tumors by inhibiting mGlu1 receptor. BAY 36-7620 suppresses AKT phosphorylation in A549 tumors. BAY 36-762 has neuroprotective effect in acute subdural hematoma rat model.BAY 36-7620 is used in non-small cell lung cancer and breast cancer research.
    BAY 36-7620
  • HY-107517
    UBP 1112 339526-74-8 98%
    UBP 1112 is a selective group III mGluR antagonist, with a Kd of 5.1 μM.UBP 1112 shows 96-fold affinity for group III over group II mGlu receptor (Kd, 488 μM), and shows no significant activity at group I mGlu receptor or iGlu receptor.
    UBP 1112
Cat. No. Product Name / Synonyms Application Reactivity